The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | Treating patients with PNH and bone marrow failure
In this video, Jeff Szer, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, briefly comments on the effectiveness of treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH) and a bone marrow failure syndrome, such as aplastic anemia. According to Prof. Szer, available data suggest that treatment for one condition does not impact the responsiveness to therapy for the other, and that they should be regarded as related but independent clinical entities when therapy is selected. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a complicated question and it refers to whether the impact of treatment for bone marrow failure, for example, either aplastic anemia or hypocellular myelodysplasia, impacts on the disease PNH or impacts on its treatment and vice versa. And I think most of the evidence that we have, and much of this came from our previous registry from the global registry that was running under the Alexion banner for many years...
This is a complicated question and it refers to whether the impact of treatment for bone marrow failure, for example, either aplastic anemia or hypocellular myelodysplasia, impacts on the disease PNH or impacts on its treatment and vice versa. And I think most of the evidence that we have, and much of this came from our previous registry from the global registry that was running under the Alexion banner for many years. But the data that we had suggested that there was actually no difference in the responsiveness of patients with aplastic anemia and PNH that required treatment, either of the aplastic anemia treated with immunosuppressive therapy or the PNH treated with complement blockade. So they need to be regarded as related but independent clinical entities when therapy is chosen.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Financial relationship (not shares) with Alexion, Sobi, Novartis.
